Pfizer Reports Young Boy Dies From Cardiac Arrest After Participating in Gene Therapy Study
Pharmaceutical giant Pfizer has reported a young boy has died due to cardiac arrest after receiving the company’s experimental gene therapy for Duchenne muscular dystrophy.
A Pfizer spokesperson told Reuters in an exclusive email, “A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study.”
Pfizer’s gene therapy trial is currently testing children two to three-year-olds who have Duchenne muscular dystrophy.
According to Johns Hopkins Medicine, Duchenne muscular dystrophy (DMD) “is caused by a genetic problem in producing dystrophin, a protein that protects muscle fibers from breaking down when exposed to enzymes.”
BREAKING: A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy,
